US EditionPublished • loading... • Updated
Drugmakers Plan 4% Median Price Increase on 350 Medicines in U.S. for 2026: Report
At least 350 brand-name drugs will see a median U.S. list price increase of about 4% in 2026 despite government pressure to lower costs, data from 3 Axis Advisors shows.
- On January 1, brand-name drugmakers plan to raise U.S. list prices for at least 350 drugs, with a median increase of about 4%, Reuters' exclusive 3 Axis Advisors data show.
- Facing political pressure from the Trump administration, Pfizer Inc. told Reuters its list-price increases remain below inflation and support research and rising business costs for U.S. patients.
- Manufacturers also signalled a small number of cuts, with about nine drugs slated for reductions, including Boehringer Ingelheim's Jardiance cut by more than 40%.
- The U.S. government is negotiating lower Medicare prices for Jardiance and nine other drugs for people 65 and older in 2026, while Reuters reported planned hikes already exceed last year’s 250 drugs.
- The administration has struck pricing deals with 14 manufacturers covering some drugs sold through Medicaid and to cash-paying consumers, despite U.S. patients paying the most for prescription drugs.
Insights by Ground AI
41 Articles
41 Articles
Makers Hike Prices on 350 Drugs Despite Trump Pressure
Drug prices are poised to climb in the new year on hundreds of medicines even as the Trump administration publicly leans on pharmaceutical companies to bring costs down. According to data from research firm 3 Axis Advisors, at least 350 brand-name drugs are set for list price increases in 2026,...
·Miami, United States
Read Full Article
Coverage Details
Total News Sources41
Leaning Left8Leaning Right2Center22Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 25%
C 69%
Factuality
To view factuality data please Upgrade to Premium
